ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials for Dry Age-Related Macular Degeneration and Stargardt's Macular Dystrophy
Patients in U.S. Clinical Trials Injected with 150,000 human embryonic stem cell-(hESC) derived Retinal Pigment Epithelial Cells
MARLBOROUGH, Mass. — April 1, 2013 – Advanced Cell Technology, Inc.(“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of patients in the third patient cohort, in each of its two U.S. clinical trials for forms of macular degeneration. The patients were injected with 150,000 human embryonic stem cell-(hESC) derived retinal pigment epithelial (RPE) cells, as compared with the 100,000-cell dose used in the previous three patients of the second cohort. The Stargardt’s Macular Dystrophy (SMD) patient was treated on Wednesday, March 27, at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, with the patient with dry age-related macular degeneration (dry AMD) having been treated the prior day, at another clinical trial site. Both patients successfully underwent the outpatient transplantation surgery, and are recovering uneventfully. http://www.advancedcell.com/news-and-media/press-releases/act-initiates-treatment-of-higher-dosage-cohort-in-clinical-trials-for-dry-age-related-macular-degeneration-and-stargardt-s-macular-dystrophy/index.asp
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.